冠状动脉旁路移植术后双联抗血小板治疗相关上消化道黏膜损伤预防中的质子泵抑制剂(DACAB-GI-2):随机对照试验研究方案
DACAB-GI-2为前瞻性、单中心、开放标签、平行随机对照试验,拟纳入232例CABG后计划或已启动12个月DAPT的患者,按1:1随机接受12个月或1个月泮托拉唑治疗,主要结局为随机化后12个月内经食管胃十二指肠镜评估的胃十二指肠糜烂和溃疡发生率(改良Lanza评分)。
要点
- CABG后DAPT与出血风险相关,其中消化道出血占一半以上。
- PPI在降低上消化道出血风险时可能增加主要心血管不良事件风险。
- 研究比较CABG后DAPT患者泮托拉唑治疗12个月与1个月的有效性和安全性。
核心结论
- 本研究旨在比较CABG后DAPT患者泮托拉唑治疗12个月与1个月在预防上消化道黏膜损伤方面的有效性和安全性。
研究设计与样本
- DACAB-GI-2为前瞻性、单中心、开放标签、平行随机对照试验,共纳入232例CABG后立即计划或启动12个月DAPT(氯吡格雷联合阿司匹林或替格瑞洛联合阿司匹林)的合格受试者。
- 受试者按1:1比例随机分配至12个月泮托拉唑治疗组或1个月治疗组。
主要发现
- 主要结局为随机化后12个月内经食管胃十二指肠镜(EGD)评估的胃十二指肠糜烂和溃疡发生率,基于改良Lanza评分。
- 次要结局包括反流性食管炎和上消化道出血。
- 其他预设结局包括主要不良心血管事件、桥血管失败和全因死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dual antiplatelet therapy (DAPT) is recommended in secondary prevention after coronary artery bypass grafting (CABG), but it is inevitably associated with the risk of bleeding, of which gastrointestinal bleeding accounts for more than half. Proton pump inhibitors (PPIs) may increase the risk of major cardiovascular adverse events when reducing the risk of upper gastrointestinal bleeding. Therefore, the optimal duration of a PPI in combination with DAPT is unclear. METHODS: The "Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury in Patients on Dual Antiplatelet Therapy after CABG" (DACAB-GI-2) study is a prospective, single-center, open-label, parallel, randomized controlled trial. A total of 232 eligible subjects who are scheduled or initiated on DAPT (clopidogrel plus aspirin or ticagrelor plus aspirin) for 12 months immediately after CABG will be enrolled and be randomized in a 1:1 ratio to either a 12-month pantoprazole treatment arm or a 1-month treatment arm. The primary outcome is to assess the rate of gastroduodenal erosions and ulcers evaluated by esophagogastroduodenoscopy (EGD) within 12 months after randomization, based on the modified Lanza score. Secondary outcomes include reflux esophagitis and upper gastrointestinal bleeding. Other pre-specified outcomes include major adverse cardiovascular events, graft failure, and all-cause death. DISCUSSION: This study aims to compare the efficacy and safety of 12 months and 1 month of pantoprazole treatment in preventing DAPT-related upper gastrointestinal mucosal injury after CABG. TRIAL REGISTRATION: ClinicalTrials.gov NCT03908593 .
引用
- Zhu Y, Wang X, Yang Y, et al. Proton pump inhibitor in the prevention of upper gastrointestinal mucosal injury associated with dual antiplatelet therapy after coronary artery bypass grafting (DACAB-GI-2): study protocol for a randomized controlled trial. Trials. 2022. PMID: 35840999. doi:10.1186/s13063-022-06464-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。